VWA3B Inhibitors
Chemical inhibitors of VWA3B function by disrupting the cellular structures and processes that are essential for the protein's role in cell adhesion and cytoskeletal organization. Paclitaxel, for example, stabilizes microtubules, preventing their disassembly and consequently interfering with the cell division process, which can lead to functional inhibition of VWA3B. Similarly, Vinblastine and Colchicine target tubulin to inhibit microtubule polymerization, while Nocodazole disassembles microtubules, all contributing to the disruption of the structural integrity necessary for VWA3B's activity. Cytochalasin D and Latrunculin A exert their effects on the actin cytoskeleton; Cytochalasin D inhibits actin filament formation, and Latrunculin A prevents actin polymerization, both leading to disruptions that can inhibit VWA3B. Swinholide A severs and depolymerizes actin filaments, further contributing to the impairment of the actin structure, which is crucial for VWA3B function.
In addition to chemicals that target cytoskeletal filaments directly, other inhibitors interfere with the regulatory pathways of the cytoskeleton. Blebbistatin and ML-7 hinder the functions of myosin II and myosin light chain kinase, respectively. By doing so, they impede cellular contractility and motility, which are associated with VWA3B's role in cell adhesion. Y-27632 specifically inhibits Rho-associated protein kinase (ROCK), which is pivotal in actin organization, thus affecting VWA3B functionality by altering the cell shape and cytoskeletal arrangements. Jasplakinolide, in contrast, stabilizes actin filaments and, by preventing their normal turnover, can also disrupt cell adhesion processes involving VWA3B. Withaferin A targets vimentin, a key component of the intermediate filament network, and its depolymerization effect can lead to cytoskeletal disruptions, indirectly inhibiting the function of VWA3B. Each of these chemicals, through their distinct actions on the cells' structural components or regulatory mechanisms, can contribute to the inhibition of VWA3B, demonstrating the complexity of cellular systems and the multifaceted nature of protein function regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $40.00 $73.00 $217.00 $242.00 $724.00 $1196.00 | 39 | |
Paclitaxel stabilizes microtubules and thereby inhibits their disassembly, which is essential for mitotic spindle formation and cell division. Since VWA3B is involved in cell adhesion and cytoskeletal organization, paclitaxel's action on microtubules can lead to functional inhibition of VWA3B by disrupting cellular structures that are necessary for its activity. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
Blebbistatin is a selective inhibitor of myosin II ATPase activity. By inhibiting myosin II, blebbistatin impedes actomyosin contractility and cellular motility. Because VWA3B is associated with cellular adhesion, the inhibition of myosin II can disrupt the cytoskeletal dynamics and cell adhesion processes, indirectly inhibiting VWA3B function. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
ML-7 is an inhibitor of myosin light chain kinase (MLCK). MLCK phosphorylation of myosin light chains is critical for cytoskeletal organization and cell contraction. Inhibition of MLCK by ML-7 could therefore disrupt processes that are essential for the proper functioning of VWA3B, which is involved in cell adhesion and structure. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). ROCK is involved in actin cytoskeleton organization. By inhibiting ROCK, Y-27632 disrupts cytoskeletal arrangements and cell shape, which are vital for the functioning of VWA3B in cell adhesion and structure. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
Cytochalasin D disrupts actin polymerization and is known to inhibit actin filament formation. As VWA3B is involved in cell adhesion, the alteration in actin cytoskeleton caused by cytochalasin D can impair the adhesive functions where VWA3B plays a role. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
Latrunculin A binds to actin monomers and inhibits their polymerization. Given that VWA3B's role is associated with cell adhesion and the cytoskeleton, the inhibition of actin polymerization by latrunculin A leads to a disruption of the cytoskeletal integrity, thereby inhibiting VWA3B's function. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $98.00 $315.00 $2244.00 $4396.00 $17850.00 $34068.00 | 3 | |
Colchicine binds to tubulin and inhibits its polymerization, leading to the disassembly of microtubules. This action compromises cell division and cytoskeletal integrity. As VWA3B is involved in cytoskeletal-related processes, colchicine indirectly inhibits its function by dismantling the microtubule network. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole is a microtubule-depolymerizing agent that interferes with microtubule dynamics. By disrupting microtubules, nocodazole can indirectly inhibit VWA3B by altering the cellular architecture and processes dependent on an intact cytoskeleton. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and prevents their depolymerization. The stabilization of actin filaments can result in the disruption of normal cytoskeletal turnover, which is necessary for cell adhesion where VWA3B is implicated, thus indirectly inhibiting its function. | ||||||
Withaferin A | 5119-48-2 | sc-200381 sc-200381A sc-200381B sc-200381C | 1 mg 10 mg 100 mg 1 g | $127.00 $572.00 $4090.00 $20104.00 | 20 | |
Withaferin A is known to bind to vimentin and induces its depolymerization. Vimentin is a component of the intermediate filament network of the cytoskeleton. Disruption of this network through vimentin depolymerization can impede functions related to cellular structure and adhesion, where VWA3B is involved. | ||||||